Social isolation refers to limited social contact and interaction with others, resulting in feelings of loneliness and disconnection. It disproportionately affects the elderly due to factors like loss of friends and family, retirement, reduced mobility, ageism, and limited access to technology. The elderly are at higher risk of social isolation as they may experience a shrinking social circle and face barriers to social participation. Social isolation has significant detrimental effects on their mental and physical well-being, leading to increased rates of depression, anxiety, cognitive decline, and reduced quality of life. Addressing social isolation among the elderly is crucial for promoting their overall health and happiness.
Social prescribing is a healthcare approach that recognises the importance of social factors in overall well-being. It involves connecting individuals with non-medical activities and community resources to improve their health and quality of life. Healthcare professionals, such as doctors or social workers, “prescribe” activities like art classes, gardening, exercise groups, or support groups, which can address underlying social determinants of health and promote holistic well-being. By addressing social isolation, mental health, and lifestyle factors, social prescribing aims to enhance individual health outcomes and reduce the burden on healthcare services.
Social prescribing provides support in various areas of people’s lives, leading to increased confidence, improved navigation of systems, and enhanced friendships and trust in healthcare, while communities should be designed in an age-friendly way to prevent isolation.
In Part 1 of the Models of Care on Social Prescribing, Australian Health Journal spoke to 4 people advocating for social prescribing in Australia:
- Dr Michelle Lim, Scientific Chair and Chairperson, Ending Loneliness Together
- Patricia Sparrow, Chief Executive Officer, COTA Australia
- Dr Paresh Dawda, General Practitioner, Director and Principal, Next Practice Deakin. All well as being a UK GP
- Tracey Johnson, Chief Executive Officer, Inala Primary Care
The discussions with these advocates emphasise social prescribing is a necessary solution to address isolation, loneliness, and stress, but it requires more resources, funding, and support to make it accessible and affordable for individuals, particularly older Australians.
-
Redefining diversity in clinical trials
Ensuring inclusion, diversity, equity and patient input in the development of novel drugs and medical devices has become well accepted in health care. However appropriate implementation of these elements has been a challenge for many. Only by implementing these conscious inputs can patient outcomes be improved and health disparities in marginalised groups be addressed.
Australian Health Journal spoke to Gillian Mason, Consumer and Community Involvement Lead at Hunter Medical Research Institute in Newcastle, NSW on this topic discussed at the recent ARCS Conference in Sydney.
-
Pathology technology at a crossroads
The CEO of Pathology Technology Australia, Dean Whiting spoke with Australian Health Journal about the following:
– Pathology Technology Australia’s key priorities in the coming years
– Current local capability in pathology technology compared to other countries
– How the health system supports change and adoption of pathology technology
– How pathology is perceived by the public and in government as well as how developments in pathology technology are followed and understood
– Observations in the Strengthening Medicare Taskforce ReportIn the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.
-
Continuing education program leads to better conversations
Medicines Australia’s Continuing Education Program (CEP) is designed to educate medical representatives to a recognised industry standard. Dr Tristan Ling, CEP Academic Lead and Project Manager at the College of Health and Medicine, University of Tasmania talks about the 900 students that come through the program each year.
The CEP is primarily directed at medical representatives working within the prescription medicines industry, but is also recommended to people who may not be currently employed within the industry but would like to pursue a career as a medical representative. It is also available to personnel working for organisations interacting with the pharmaceutical industry.
